Handelsbanken Fonder AB Decreases Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Handelsbanken Fonder AB cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 12.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,300 shares of the company's stock after selling 11,000 shares during the period. Handelsbanken Fonder AB owned about 0.26% of Krystal Biotech worth $13,396,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech in the 4th quarter worth about $95,000. Covestor Ltd raised its stake in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after purchasing an additional 642 shares during the last quarter. GAMMA Investing LLC raised its stake in Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after purchasing an additional 432 shares during the last quarter. US Bancorp DE raised its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the last quarter. Finally, Certuity LLC acquired a new position in Krystal Biotech in the 4th quarter valued at about $214,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on KRYS shares. Citigroup cut their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $211.13.

Krystal Biotech Trading Down 2.3%

Shares of NASDAQ KRYS traded down $3.26 on Friday, reaching $137.07. 295,086 shares of the company traded hands, compared to its average volume of 304,820. The company has a 50 day moving average of $146.57 and a 200 day moving average of $161.50. The stock has a market capitalization of $3.96 billion, a PE ratio of 45.84 and a beta of 0.65. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).